用於治療發炎性腸道疾病的蛋白質水解物市場機會、成長促進因素、產業趨勢分析及預測（2025-2034年）

2024 年全球用於治療發炎性腸道疾病的蛋白質水解物市場價值為 9.956 億美元，預計到 2034 年將以 5.5% 的複合年成長率成長至 17 億美元。

產業擴張持續受益於強力的科學支持，近期臨床研究結果進一步證實了其治療價值。這些產品在擁有完善診斷體系和先進醫療能力的地區，尤其是在發炎性腸道疾病（IBD）檢出率較高的市場，正獲得廣泛認可。亞太等快速成長地區，由於人們對IBD的認知度不斷提高以及發病率呈上升趨勢（尤其是在東亞地區），市場成長速度正在加快。重塑市場格局的另一個動力是全球對植物性營養的日益成長的需求。隨著純素食和素食生活方式的普及，對植物蛋白水解物的需求急劇上升，相關研究也證實了其在控制發炎和促進腸道健康方面的潛力。此外，專業醫療營養的普及也推動了市場需求，蛋白水解物正成為慢性消化系統疾病患者治療性飲食策略的重要組成部分。

2024年，深度水解蛋白製劑市佔率達到38%，這主要得益於其適用於重度發炎性腸道疾病以及市場對高消化率、低抗原解決方案的需求。這些產品被加工成更小的營養成分，有助於減少免疫觸發因素，同時仍能提供維持腸道功能和促進康復所需的關鍵營養素。由於在支持需要精準營養介入的患者方面卓有成效，臨床接受度持續上升。

2024年，腸內營養市佔率達42%。此類別廣泛應用於需要透過餵食系統或流質飲食管理獲得營養支持的發炎性腸道疾病患者。臨床證據不斷強調腸內營養的益處，尤其是在常規療法效果不佳的情況下。其強勁的市場表現也反映出人們對特殊營養方案在疾病急性發作控制方面的持續依賴。

2024年，美國用於治療發炎性腸道疾病（IBD）的蛋白質水解物市場規模預計將達到3.304億美元，主要得益於龐大的IBD患者族群（約佔總人口的0.72%）。該地區完善的醫療保健體系、活躍的臨床研究環境、支持性的醫療營養法規以及保險覆蓋範圍，都促進了該產品的快速普及。主要研究機構正在進行的研究也凸顯了該地區致力於改善治療性營養並保持其領先地位的決心。

參與發炎性腸道疾病蛋白水解物市場的主要公司包括Kerry Group plc、Arla Foods Ingredients、Abbott Nutrition、Nestle Health Science、Fresenius Kabi、Nutricia、Reckitt、Ajinomoto和DSM Nutritional Products。這些公司正透過大力投資臨床研究來擴大市場佔有率，以驗證治療優勢並獲得更廣泛的醫學認可。許多製造商正在改進生產技術，以提高蛋白質消化率並降低抗原性，從而滿足患有嚴重胃腸道疾病患者的需求。此外，為了迎合消費者對純素食和素食醫療營養品日益成長的需求，各公司也正在拓展植物性水解物產品組合。與醫療機構進行策略合作、致力於研發先進的腸內營養製劑以及拓展高成長地區是其競爭策略的核心。

目錄

第1章：方法論與範圍

第2章：執行概要

第3章：行業洞察

• 產業生態系分析
  • 供應商格局
  • 利潤率
  • 每個階段的價值增加
  • 影響價值鏈的因素
  • 中斷
• 產業影響因素
  • 成長促進因素
  • 產業陷阱與挑戰
  • 市場機遇
• 成長潛力分析
• 監管環境
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
• 波特的分析
• PESTEL 分析
• 價格趨勢
  • 按地區
• 未來市場趨勢
• 技術與創新格局
  • 當前技術趨勢
  • 新興技術
• 專利格局
• 貿易統計（HS編碼）（註：僅提供重點國家的貿易統計資料）
  • 主要進口國
  • 主要出口國
• 永續性和環境方面
  • 永續實踐
  • 減少廢棄物策略
  • 生產中的能源效率
  • 環保舉措
• 碳足跡考量

第4章：競爭格局

• 介紹
• 公司市佔率分析
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 關鍵進展
  • 併購
  • 合作夥伴關係與合作
  • 新產品發布
  • 擴張計劃

第5章：市場規模及預測：依產品類型分類，2021-2034年

• 主要趨勢
• 深度水解蛋白質產品
• 部分水解蛋白產品
• 胺基酸配方
• 其他

第6章：市場規模及預測：依原料分類，2021-2034年

• 主要趨勢
• 乳製品水解物
  • 乳清蛋白水解物
  • 酪蛋白水解物
  • α-乳清蛋白濃縮物
  • 其他
• 植物水解物
  • 米蛋白水解物
  • 豌豆蛋白水解物
  • 大豆蛋白水解物
  • 其他
• 海洋來源水解物
• 其他

第7章：市場規模及預測：依應用領域分類，2021-2034年

• 主要趨勢
• 腸內營養
• 口服營養補充品
• 醫用食品
• 其他

第8章：市場規模及預測：依最終用途分類，2021-2034年

• 主要趨勢
• 醫院和臨床機構
• 家庭醫療保健
• 專業營養中心
• 其他

第9章：市場規模及預測：依地區分類，2021-2034年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第10章：公司簡介

• Kerry Group
• Arla Foods Ingredients
• Abbott Nutrition
• Nestle Health Science
• Fresenius Kabi
• Nutricia
• Reckitt
• Ajinomoto
• DSM Nutritional Products

The Global Protein Hydrolysates for Inflammatory Bowel Disease Market was valued at USD 995.6 million in 2024 and is estimated to grow at a CAGR of 5.5% to reach USD 1.7 billion by 2034.

Industry expansion continues to benefit from strong scientific support, as recent clinical findings reinforce their therapeutic value. These products are gaining traction across regions with established diagnostic systems and advanced healthcare capabilities, particularly in markets where IBD detection rates are high. Areas experiencing rapid growth, such as Asia Pacific, are accelerating due to rising awareness and increasing incidence trends, especially in East Asia. Another major force reshaping the market is the growing global shift toward plant-based nutrition. As vegan and vegetarian lifestyles expand, demand for plant-derived protein hydrolysates is rising sharply, supported by research that highlights their potential in managing inflammation and supporting gut health. Market interest is also driven by the broader trend toward specialized medical nutrition, where protein hydrolysates are becoming an important part of therapeutic dietary strategies for individuals managing chronic digestive conditions.

The extensively hydrolyzed protein formulations segment held a 38% share in 2024, driven by their suitability for severe inflammatory bowel disease and the need for highly digestible, low-antigen solutions. These products are processed into smaller nutritional components, helping reduce immune triggers while still supplying key nutrients essential for maintaining intestinal function and promoting recovery. Their clinical acceptance continues to rise due to their effectiveness in supporting patients requiring precise nutritional interventions.

The enteral nutrition segment held a 42% share in 2024. This category is widely used for individuals with inflammatory bowel disease who require nutritional support through feeding systems or liquid-based dietary management. Clinical evidence consistently highlights the benefits of enteral nutrition, particularly in cases where conventional therapies are insufficient, and its strong performance reflects continued reliance on specialized nutritional regimens for managing disease flares.

U.S. Protein Hydrolysates for Inflammatory Bowel Disease Market generated USD 330.4 million in 2024, supported by a significant IBD patient pool, with about 0.72% of the population affected. The region's robust healthcare systems, active clinical research landscape, supportive regulations for medical nutrition, and insurance coverage contribute to strong adoption. Ongoing studies led by major research institutions underscore the region's commitment to improving therapeutic nutrition and maintaining its leadership position.

Key companies participating in the Protein Hydrolysates for Inflammatory Bowel Disease Market industry include Kerry Group plc, Arla Foods Ingredients, Abbott Nutrition, Nestle Health Science, Fresenius Kabi, Nutricia, Reckitt, Ajinomoto, and DSM Nutritional Products. Companies in the Protein Hydrolysates for Inflammatory Bowel Disease Market are widening their market footprint by investing heavily in clinical research to validate therapeutic advantages and secure stronger medical acceptance. Many manufacturers are refining production technologies to enhance protein digestibility and reduce antigenicity, helping them meet the needs of patients with severe gastrointestinal challenges. Firms are also diversifying their portfolios with plant-based hydrolysates to align with rising consumer preference for vegan and vegetarian medical nutrition. Strategic collaborations with healthcare institutions, product innovation geared toward advanced enteral formulations, and expansion into high-growth regions are central to their competitive approach.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Product type
  • 2.2.2 Source material
  • 2.2.3 Application
  • 2.2.4 End Use
• 2.3 TAM analysis, 2025-2034
• 2.4 CXO perspectives: Strategic imperatives
  • 2.4.1 Executive decision points
  • 2.4.2 Critical success factors
• 2.5 Outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Profit margin
  • 3.1.3 Value addition at each stage
  • 3.1.4 Factor affecting the value chain
  • 3.1.5 Disruptions
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
  • 3.2.2 Industry pitfalls and challenges
  • 3.2.3 Market opportunities
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East & Africa
• 3.5 Porter's analysis
• 3.6 PESTEL analysis
• 3.7 Price trends
  • 3.7.1 By region
• 3.8 Future market trends
• 3.9 Technology and innovation landscape
  • 3.9.1 Current technological trends
  • 3.9.2 Emerging technologies
• 3.10 Patent landscape
• 3.11 Trade statistics (HS code) (Note: the trade statistics will be provided for key countries only)
  • 3.11.1 Major importing countries
  • 3.11.2 Major exporting countries
• 3.12 Sustainability and environmental aspects
  • 3.12.1 Sustainable practices
  • 3.12.2 Waste reduction strategies
  • 3.12.3 Energy efficiency in production
  • 3.12.4 Eco-friendly initiatives
• 3.13 Carbon footprint considerations

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 By region
    • 4.2.1.1 North America
    • 4.2.1.2 Europe
    • 4.2.1.3 Asia Pacific
    • 4.2.1.4 Latin America
    • 4.2.1.5 Middle East & Africa
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Size and Forecast, By Product Type, 2021-2034 (USD Billion, Kilo Tons)

• 5.1 Key trends
• 5.2 Extensively hydrolyzed protein products
• 5.3 Partially hydrolyzed protein products
• 5.4 Amino acid-based formulations
• 5.5 Others

Chapter 6 Market Size and Forecast, By Source Material, 2021-2034 (USD Billion, Kilo Tons)

• 6.1 Key trends
• 6.2 Dairy-derived hydrolysates
  • 6.2.1 Whey protein hydrolysates
  • 6.2.2 Casein hydrolysates
  • 6.2.3 Alpha-lactalbumin concentrates
  • 6.2.4 Others
• 6.3 Plant-based hydrolysates
  • 6.3.1 Rice protein hydrolysates
  • 6.3.2 Pea protein hydrolysates
  • 6.3.3 Soy protein hydrolysates
  • 6.3.4 Others
• 6.4 Marine-derived hydrolysates
• 6.5 Others

Chapter 7 Market Size and Forecast, By Application, 2021-2034 (USD Billion, Kilo Tons)

• 7.1 Key trends
• 7.2 Enteral nutrition
• 7.3 Oral nutritional supplements
• 7.4 Medical foods
• 7.5 Others

Chapter 8 Market Size and Forecast, By End Use, 2021-2034 (USD Billion, Kilo Tons)

• 8.1 Key trends
• 8.2 Hospitals & clinical settings
• 8.3 Home healthcare
• 8.4 Specialized nutrition centers
• 8.5 Others

Chapter 9 Market Size and Forecast, By Region, 2021-2034 (USD Billion, Kilo Tons)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 UK
  • 9.3.2 Germany
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 South Korea
  • 9.4.5 Australia
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East & Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East & Africa

Chapter 10 Company Profiles

• 10.1 Kerry Group
• 10.2 Arla Foods Ingredients
• 10.3 Abbott Nutrition
• 10.4 Nestle Health Science
• 10.5 Fresenius Kabi
• 10.6 Nutricia
• 10.7 Reckitt
• 10.8 Ajinomoto
• 10.9 DSM Nutritional Products